Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects

Clinical and Vaccine Immunology

Volumn 19, Issue 12, 2012, Pages 1943-1948

  Bihari, Iván ^a   Pánczél, Gyula ^b   Kovacs, Jozsef ^c   Beygo, Jenny ^c   Fragapanec, Elena ^c,d  

^a Pestszentlorinc Pestszentimre Health Service KFT   (Hungary)

^b BÁCS KISKUN COUNTY TEACHING HOSPITAL   (Hungary)

^c Clinical Research and Development   (United States)

^d NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIGEN;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CHILL; CROSS REACTION; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ECCHYMOSIS; FATIGUE; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HEMOLYSIS; HUMAN; HUNGARY; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; INJECTION SITE ECCHYMOSIS; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; SWEATING; VIRUS NEUTRALIZATION; VIRUS STRAIN; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CROSS REACTIONS; DRUG TOXICITY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; POLYSORBATES; SQUALENE; YOUNG ADULT;

EID: 84870455803     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00373-12     Document Type: Article

References (39)

1. Alghisi F, et al. 2011. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. Thorax 66:259-260.
2. Banzhoff A, et al. 2009. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 4:e4384. doi:10.1371/journal.pone.0004384.
3. Banzhoff A, Haertel S, Praus M. 2011. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum. Vaccin. 7:539-548.
4. Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E. 2010. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin. Ther. 32:2186-2197.
5. Black S, et al. 2010. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 28:7331-7336.
6. Crucitti A, Tsai TF. 2011. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy: a six-month update. Scand. J. Infect. Dis. 43:993.
7. El Sahly H. 2010. MF59 as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev. Vaccines 9:1135-1141.
8. Esposito S, et al. 2010. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with beta-thalassemia major. Vaccine 28:7825-7828.
9. Esposito S, et al. 2011. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol. Dial. Transplant. 26:2018-2024.
10. European Agency for the Evaluation of Medicinal Products. 1997. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. European Agency for the Evaluation of Medicinal Products, London, United Kingdom. http://www.emea.europa.eu/docs/en- GB/document-library/Scientific-guideline/2009/09/WC500003945.pdf.
11. Ferguson NM, et al. 2006. Strategies for mitigating an influenza pandemic. Nature 442:448-452. (Pubitemid 44264793)
12. Fragapane E, et al. 2010. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin. Vaccine Immunol. 17:1817-1819.
13. Galli G, et al. 2009. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl. Acad. Sci. U. S. A. 106:7962-7967.
14. Galli G, et al. 2009. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. U. S. A. 106:3877-3882.
15. Imai M, et al. 2012. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486:420-428.
16. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. 2008. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect. Dis. 8:650-658.
17. Kajaste-Rudnitski A, et al. 2011. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 25:177-183.
18. Khurana S, et al. 2010. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2:15ra5. doi:10.1126/scitranslmed.3000624.
19. Khurana S, et al. 2011. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3:85ra48. doi:10.1126/scitranslmed.3002336.
20. Leroux-Roels I, et al. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589. (Pubitemid 47247854)
21. Lopez P, et al. 2011. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J. Infect. Dis. 203:1719-1728.
22. Meier S, et al. 2011. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 29:3548-3557.
23. Nicholson KG, et al. 2001. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943. (Pubitemid 32568336)
24. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. 2011. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines 10:447-462.
25. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. 2009. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27:6959-6965.
26. Rockman S, Brown L. 2010. Pre-pandemic and pandemic influenza vaccines. Hum. Vaccin. 6:792-801.
27. Schild GC, Pereira MS, Chakraverty P. 1975. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull. World Health Organ. 52:43-50.
28. Stephenson I, et al. 2008. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med. 359:1631-1633.
29. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. 2004. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect. Dis. 4:499-509. (Pubitemid 39077920)
30. Tsai T, et al. 2010. Exposure to MF59-adjuvanted influenza vaccines during pregnancy-a retrospective analysis. Vaccine 28:1877-1880.
31. Tsai TF, et al. 2011. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand. J. Infect. Dis. 43:702-706.
32. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. 2009. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27:6291-6295.
33. Vesikari T, et al. 2010. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126:e762-e770.
34. Vesikari T, et al. 2011. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365:1406-1416.
35. Watts G. 2011. New findings on H1N1 vaccine prompt revised prescribing advice. BMJ 342:d2524. doi:10.1136/bmj.d2524.
36. World Health Organization. 2012. Cumulative number of confirmed human cases of avian influenza A (H5N1) reported to WHO. World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/human-animal-interface/H5N1- cumulative-table-archives/en/index.html. Accessed 31 May 2012.
37. World Health Organization. 2009. Pandemic influenza preparedness and response. WHO guidance document. World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/resources/documents/pandemic-guidance-04-2009/en/ index.html.
38. Zhao ZM, Shortridge KF, Garcia M, Guan Y, Wan XF. 2008. Genotypic diversity of H5N1 highly pathogenic avian influenza viruses. J. Gen. Virol. 89:2182-2193.
39. Zuccotti GV, et al. 2011. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. Diabet. Med. 28:1530-1536.